Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists

Drug Discovery Today

Volumn 10, Issue 10, 2005, Pages 693-702

  Lange, Jos H M ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CP 272871; CP 945598; DRONABINOL; NESS 0327; NIDA 41020; NOLADIN ETHER; O 1248; O 1269; O 1803; RIMONABANT; SLV 326; UNCLASSIFIED DRUG;

DRUG CONFORMATION; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; LIGAND BINDING; OBESITY; PHARMACOPHORE; REVIEW; SMOKING CESSATION; STRUCTURE ACTIVITY RELATION;

CHEMISTRY, PHARMACEUTICAL; HUMANS; MOLECULAR CONFORMATION; OBESITY; RECEPTOR, CANNABINOID, CB1; SMOKING CESSATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19444368081     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03427-6     Document Type: Review

References (107)

1. Mechoulam R. Towards cannabinoid drugs - revisited Prog. Med. Chem. 35 1998 199 243
2. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans Addiction 91 1996 1585 1614
3. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86 1964 1646 1647
4. Wilson R., Nicoll R.A. Endocannabinoid signaling in the brain Science 296 2002 678 682
5. De Petrocellis L. The endocannabinoid system: A general view and latest additions Br. J. Pharmacol. 141 2004 765 774
6. Matsuda L.A. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
7. Munro S. Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 62
8. 1 cannabinoid receptors and on demand defence against excitotoxicity Science 302 2003 84 88
9. Di Marzo V. The endocannabinoid system and its therapeutic application Nat. Rev. Drug Discov. 3 2004 771 784
10. Fowler C. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs Trends Pharmacol. Sci. 25 2004 59 61
11. Howlett A.C. Cannabinoid physiology and pharmacology: 30 years of progress Neuropharmacol. 47 2004 345 358
12. 2 receptors Pharmacol. Ther. 74 1997 129 180
13. Cota D. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J. Clin. Invest. 112 2003 423 431
14. Klein T.W. Cannabinoid receptors and immunity Immunol. Today 19 1998 373 381
15. Walter L. Non-psychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405
16. 2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study Synapse 53 2004 208 213
17. 2 receptor-dependent mechanism Mol. Pharmacol. 65 2004 999 1007
18. Sheng W.S. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1β stimulated human astrocytes Glia 49 2005 211 219
19. Wiley J.L., Martin B.R. Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes Chem. Phys. Lipids 121 2002 57 63
20. + current J. Biol. Chem. 278 2003 46188 46194
21. Pertwee R.G. Novel pharmacological targets for cannabinoids Curr. Neuropharmacol. 2 2004 9 29
22. Drmota T. Screening assays for cannabinoid-ligand-type modulators of GPR55 WO patent 2004 2004074844
23. Barth F., Rinaldi-Carmona M. The development of cannabinoid antagonists Curr. Med. Chem. 6 1999 745 755
24. Adam J., Cowley P. Recent advances in the cannabinoids Expert Opin. Ther. Patents 12 2002 1475 1489
25. Reggio P.H. Pharmacophores for ligand recognition and activationinactivation of the cannabinoid receptors Curr. Pharm. Des. 9 2003 1607 1633
26. 1 cannabinoid receptor antagonists Curr. Opin. Drug Discov. Devel. 7 2004 498 506
27. Hertzog D.L. Recent advances in the cannabinoids Expert Opin. Ther. Patents 14 2004 1435 1452
28. 1 antagonists IDrugs 8 2005 53 66
29. Croxford J.L. Therapeutic potential of cannabinoids in CNS disease CNS Drugs 17 2003 179 202
30. Drysdale A.J., Platt B. Cannabinoids; Mechanisms and therapeutic applications in the CNS Curr. Med. Chem. 10 2003 2719 2732
31. Ligresti A. Possible endocannabinoid control of colorectal cancer growth Gastroenterology 125 2003 677 687
32. Smith P.F. Medicinal cannabis extracts for the treatment of multiple sclerosis Curr. Opin. Investig. Drugs 5 2004 727 730
33. Croxford J.L., Miller S.D. Towards cannabis and cannabinoid treatment of multiple sclerosis Drugs Today (Barc) 40 2004 663 676
34. 1 cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 98 2001 3662 3665
35. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain; Pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U. S. A. 100 2003 10529 10533
36. 2, a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 96 1999 14228 14233
37. 2 receptor Bioorg. Med. Chem. 7 1999 2905 2914
38. Baker D. Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
39. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models Eur. J. Neurosci. 17 2003 2750 2754
40. Klein T.W. The cannabinoid system and immune modulation J. Leukoc. Biol. 74 2003 486 496
41. Fernandez J.R., Allison D.B. Rimonabant Curr. Opin. Investig. Drugs 5 2004 430 435
42. Black S.C. Cannabinoid receptor antagonists and obesity Curr. Opin. Investig. Drugs 5 2004 389 394
43. Jandacek R.J., Woods S.C. Pharmaceutical approaches to the treatment of obesity Drug Discov. Today 9 2004 874 880
44. 1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake Endocrinology 145 2004 3224 3231
45. 1) receptor antagonist, blocks the motivational and dopamine releasing effects of nicotine in rats Behav. Pharmacol. 13 2002 451 463
46. Hungund B.L. Ethanol, endocannabinoids, and the cannabinoidergic signaling system Alcohol. Clin. Exp. Res. 26 2002 565 574
47. 1 antagonist N-piperidinyl-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J. Pharmacol. Exp. Ther. 306 2003 93 102
48. Chiang K.P. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use Hum. Mol. Genet. 13 2004 2113 2119
49. Castellano C. Cannabinoids and memory: animal studies Curr. Drug Targets CNS Neurol. Disord. 2 2003 389 402
50. 1 receptor antagonist improves memory in a delayed radial maze task Eur. J. Pharmacol. 477 2003 213 217
51. Da Silva G.E. Potentiation of penile erection and yawning responses to apomorhine by cannabinoid receptor antagonists in rats Neurosci. Lett. 349 2003 49 52
52. 1 receptors in the paraventricular nucleus of male rats induces penile erection Neurosci. Lett. 359 2004 17 20
53. 1 receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation Br. J. Pharmacol. 134 2001 563 570
54. 1 receptors mediate the vasodilated state in advanced liver cirrhosis Nat. Med. 7 2001 827 832
55. Maccarone M. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage Lancet 355 2000 1326 1329
56. 1 receptor-mediated inhibition of noradrenaline release in the guinea pig lung Eur. J. Pharmacol. 431 2001 237 244
57. Ralston S.H. Cannabinoid receptor inverse agonism and neutral antagonists as therapeutic agents for the treatment of bone disorders WO patent 2004 2004078261
58. Bab I. methods compositions and articles of manufacture for modulating bone growth WO patent 2004 2004103410
59. 1 cannabinoid receptors and agonist-stimulated [35S]GTPgS binding in the prefrontal cortex of depressed suicidal victims Mol. Psychiatry 9 2004 184 190
60. 1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease US patent 2004 0209861
61. Meltzer H.Y. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders Am. J. Psychiatry 161 2004 975 983
62. Huffman J.W. Cannabimimetic indoles, pyrroles and indenes Curr. Med. Chem. 6 1999 705 720
63. Song Z.H., Bonner T.I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN-55,212-2 Mol. Pharmacol. 49 1996 891 896
64. 1 receptor constitutes an agonistinverse agonist binding region J. Med. Chem. 46 2003 5139 5152
65. 2 receptors: Insights gained from (E)- and (Z)-naphtylidene indenes J. Med. Chem. 41 1998 5177 5187
66. Lan R. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J. Med. Chem. 42 1999 769 776
67. 1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole- 3-carboxamide (SR141716A) J. Med. Chem. 45 2002 2708 2719
68. Nakamura-Palacios E.M. The pharmacology of SR 141716A: A review CNS Drug Rev. 5 1999 43 58
69. 1 cannabinoid receptor Biochem. Pharmacol. 60 2000 1315 1323
70. 1 cannabinoid receptor: Biochemical and pharmacological characterisation J. Pharmacol. Exp. Ther. 310 2004 905 914
71. Miscoria G. Derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4- ethyl-N-(piperidine-1-yl)-1H-pyrazole-3-carboxamide, the preparation and therapeutic uses thereof WO patent 2004 2004 058744
72. Katoch-Rouse R. Synthesis, structure-activity relationship, and evaluation of SR 141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity J. Med. Chem. 46 2003 642 645
73. Sakya S.M. Cannabinoid receptor ligands and uses thereof WO patent 2004 2004 099157
74. 1 receptor recognition and activation J. Pharmacol. Exp. Ther. 296 2001 1013 1022
75. 2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
76. 1 receptors Life Sci. 76 2005 1307 1324
77. 1 cannabinoid receptor J. Med. Chem. 45 2002 1447 1459
78. 1 receptor Mol. Pharmacol. 62 2002 1274 1287
79. 1 cannabinoid receptor antagonists J. Med. Chem. 47 2004 627 643
80. 1 receptor J. Med. Chem. 47 2004 3048 3057
81. 1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction Biopolymers 71 2003 169 189
82. Andersson H. Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail Mol. Pharmacol. 64 2003 570 577
83. 2 receptors. A docking analysis study Eur. J. Med. Chem. 40 2005 75 83
84. 1 Receptor Antagonists Chem. Pharm. Bull. (Tokyo) 50 2002 1109 1113
85. 1 cannabinoid receptor J. Pharmacol. Exp. Ther. 306 2003 363 370
86. 2 cannabinoid receptors Bioorg. Med. Chem. 11 2003 251 263
87. 1 cannabinoid receptor antagonist Magn. Reson. Chem. 41 2003 265 268
88. Bass C.E. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study Pharmacol. Biochem. Behav. 74 2002 31 40
89. Carpino P.A., Griffith D.A. Cannabinoid receptor ligands and uses thereof WO patent 2004 2004094417
90. Carpino P.A., Dow R.L. Cannabinoid receptor ligands and uses thereof WO patent 2004 2004094421
91. Carpino P.A., Dow R.L. Cannabinoid receptor ligands and uses thereof WO patent 2004 2004094429
92. Carpino P.A., Sakya S.M. Cannabinoid receptor ligands and uses thereof US patent 2004 20040248881
93. Jenkins J.L. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes J. Med. Chem. 47 2004 6144 6159
94. Moreira L., Barreiro E.J. Bioisosterism: A useful strategy for molecular modification and drug design Curr. Med. Chem. 12 2005 23 49
95. Carpino P.A. Imidazole compounds and uses thereof WO patent 2005 2005009974
96. 1 receptor antagonists related to SR141716 Bioorg. Med. Chem. Lett. 14 2004 1151 1154
97. 1 cannabinoid receptor antagonists. J. Med. Chem. 48, 1823-1838
98. 1 receptor inverse agonists Bioorg. Med. Chem. Lett. 15 2005 1441 1446
99. 1 inverse agonists Bioorg. Med. Chem. Lett. 15 2005 645 651
100. Jagerovic N. Discovery of 5-(4-chlorophenyl)-1-(2-4-dichlorophenyl)-3- hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif J. Med. Chem. 47 2004 2939 2942
101. Baker R.K. Substituted 3-alkyl and 3-alkenyl azetidine derivatives WO patent 2005 2005000809
102. 1 receptor mediated disorders WO patent 2004 2004096763
103. Davidson J.E.P. The use of azetidine carboxamide derivatives in therapy WO patent 2004 2004096209
104. Dow R.L. Cannabinoid receptor ligands and uses thereof WO patent 2004 2004035566
105. Pfizer investors news release, Groton, Connecticut, (2004) November 30: http://www.pfizer.com/are/investors_releases/2004pr/mn_2004_1130.cfm
106. Sun C. Tetrahydroquinoline derivatives as cannabinoid receptor modulators WO patent 2005 2005007628
107. 1 cannabinoid receptor ligands: Synthesis and pharmacological evaluation. J. Med. Chem. (in press)